查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球惡性間皮瘤治療藥物市場 - 2023-2030年
市場調查報告書
商品編碼
1289781

全球惡性間皮瘤治療藥物市場 - 2023-2030年

Global Malignant Mesothelioma Therapeutics Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球惡性間皮瘤治療劑市場在2022年達到2.593億美元，預計到2030年將見證有利可圖的成長，達到5.127億美元。在預測期內（2023-2030年），全球惡性間皮瘤治療藥物預計將呈現9.1%的複合成長率。

主要的行業驅動因素，包括惡性間皮瘤實例的增加，癌症治療意識的提高，石棉在各種行業中的使用不斷擴大，以及不斷擴大的技術突破，預計將支持市場擴張。

在預計的時期內，全球惡性間皮瘤治療劑市場預計將受益於複雜的治療方法的出現。此外，全球惡性間皮瘤治療劑市場可能會受到各種產品和行業中的石棉的推動，這是形成間皮瘤的一個關鍵原因。

市場動態

在早期階段診斷和治療疾病的意識運動的增加將推動市場成長

惡性間皮瘤在世界範圍內變得越來越普遍，因此有必要增加宣傳活動，以便在早期階段診斷和治療該疾病。許多團體正在提高對這一疾病的認識，並建議接觸石棉的僱員經常接受惡性間皮瘤的篩查，這有助於防止該疾病發展到晚期階段。這種認識的提高預計將對市場的整體成長產生積極的影響。

此外，煙草和吸煙消費的增加推動了惡性間皮瘤治療劑市場的發展。全球惡性間皮瘤市場的大多數公司正在與各組織合作，探索結合眾多藥物對惡性間皮瘤的影響。由於技術專利的稀缺性，許多公司正在進行以各種組合藥物為重點的臨床研究。

惡性間皮瘤的漫長潛伏期可能會阻礙市場的成長

惡性間皮瘤潛伏期長，在早期階段缺乏疾病特異性生物標記，以及用於癌症治療的創新設備的開發和批准，可能會在整個預測期內減緩惡性間皮瘤治療市場的成長。

COVID-19影響分析

全球惡性間皮瘤治療劑市場受益於COVID-19的爆發。關於COVID-19的情況，幾個細分市場的藥物需求量增加了。該行業的製藥企業大大改善了供應鏈管理，提高了研發技能，增加了生產管理和品質控制投資。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按藥物類別簡述
  • 按給藥途徑分析
  • 按終端用戶分類

第四章：動態變化

  • 影響因素
    • 驅動因素
    • 限制因素
      • 惡性間皮瘤的潛伏期長
    • 機會
      • 擴大採用先進技術
    • 影響分析

第五章：行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • COVID-19之後的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第七章：按藥物類型

  • 培美曲塞
  • 順鉑
  • 卡鉑
  • 吉西他濱
  • 長春瑞濱
  • 其他

第8章：按給藥途徑分類

  • 口服
  • 腸外

第9章：按給藥途徑分類

  • 醫院
  • 癌症中心
  • 其他

第十章：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第11章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 合併和收購分析

第十二章：公司簡介

  • Dr. Reddy's Laboratories,
  • Wellona Pharmaceuticals
  • Bristol-Myers Squibb
  • Novocure
  • Eli Lilly and Company
  • Merck
  • Manus Aktteva Biopharma LLP
  • Pfizer
  • Ono Pharmaceuticals

第十三章：附錄

簡介目錄
Product Code: PH5147

Market Overview

The Global Malignant Mesothelioma Therapeutics Market reached US$ 259.3 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 512.7 million by 2030. The global malignant mesothelioma therapeutics is expected to exhibit a CAGR of 9.1% during the forecast period (2023-2030).

The main industry drivers, including the rise in malignant mesothelioma instances, rising cancer treatment awareness, expanding use of asbestos in a variety of industries, and expanding technical breakthroughs, are anticipated to support market expansion.

Over the projected period, the global malignant mesothelioma therapeutics market is expected to benefit from the availability of sophisticated treatments. Furthermore, the global market for malignant mesothelioma therapeutics is likely to be driven by asbestos in various products and sectors, which is a key cause of mesothelioma formation.

Market Dynamics

Increased Awareness Campaigns to Diagnose and Treat the Disease at an Earlier Stage will Drive the Market Growth

Malignant mesothelioma is becoming more common worldwide, necessitating increased awareness campaigns to diagnose and treat the disease at an earlier stage. Many groups are raising awareness about the condition and recommending that asbestos-exposed employees get frequent screenings for malignant mesothelioma, which can help prevent the disease from progressing to advanced stages. This increased awareness is projected to impact market growth overall positively.

Furthermore, rising tobacco and smoking consumption propel the malignant mesothelioma therapeutics market forward. The majority of firms in the global malignant mesothelioma market are working with organizations to explore the effects of combining numerous medications on malignant mesothelioma. Due to the scarcity of technique patents, numerous companies are conducting clinical studies focusing on various combination medications.

The Long Latency Period For Malignant Mesothelioma Is Likely To Hamper The Market Growth

A long latency period for malignant mesothelioma, a lack of disease-specific biomarkers in the early stages, and the development and approval of innovative devices for cancer treatment may slow the growth of the malignant mesothelioma therapeutics market throughout the projection period.

COVID-19 Impact Analysis

The global market for malignant mesothelioma therapeutics has benefited from the COVID-19 outbreak. About the COVID-19 situation, several segments have seen an increase in drug demand. Pharmaceutical businesses in this industry have greatly improved their supply chain management, increased their R&D skills, and increased their manufacturing management and quality control investments.

Segment Analysis

Pemetrexed Drug in Drug Class Segment will Dominate in the Market by Capturing 39.1% During the Forecast Period

The preference for combination medicines over monotherapy is one of the key factors that positively influence the Pemetrexed and combination drug type sector. Combination therapies, such as chemotherapy combined with radiation, targeted antibodies, cryotherapy, or other immunotherapies, are anticipated to expand the potential indications for various drugs.

These combination therapies aim to improve survival rates significantly, as evidenced by limited clinical data compared to only surgeries or radiation therapies. Several companies have discovered that multiple pathways in tumor regulation are affected, and as a result, they seek to use combination therapy as a more effective method. These factors are likely to boost the malignant mesothelioma therapeutics market.

Geographical Analysis

North America is the Dominating Region During the Forecast Period

In 2022, the United States is a key participant in this region, accounting for approximately 39.2% of the market. Because of increased awareness about risk factors and diagnostic procedures, the malignant mesothelioma market size in North America is growing faster than in other areas. Advanced healthcare infrastructure is also expected to drive and contribute to the growth of the malignant mesothelioma therapeutics market in North America.

Competitive Landscape

The major global players include: Dr. Reddy's Laboratories, Wellona Pharmaceuticals, Bristol-Myers Squibb, Novocure, Eli Lilly and Company, Merck, Manus Aktteva Biopharma LLP, Pfizer and Ono Pharmaceuticals.

  • Why Purchase the Report?
  • To visualize the global malignant mesothelioma therapeutics market segmentation based on the type, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of malignant mesothelioma therapeutics market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The malignant mesothelioma therapeutics market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Class
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by End user

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers

Increased awareness campaigns to diagnose and treat the disease at an earlier stage

    • 4.1.2. Restraints
      • 4.1.2.1. The long latency period for malignant mesothelioma
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing adoption of advanced technologies
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Pemetrexed
  • 7.2. Cisplatin
  • 7.3. Carboplatin
  • 7.4. Gemcitabine
  • 7.5. Vinorelbine
  • 7.6. Others

8. By Route of Administration

  • 8.1. Oral
  • 8.2. Parenteral

9. By Route of Administration

  • 9.1 Hospitals
  • 9.2 Cancer Centers
  • 9.3 Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%) By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Use
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Dr. Reddy's Laboratories,
  • 12.2. Wellona Pharmaceuticals
  • 12.3. Bristol-Myers Squibb
  • 12.4. Novocure
  • 12.5. Eli Lilly and Company
  • 12.6. Merck
  • 12.7. Manus Aktteva Biopharma LLP
  • 12.8. Pfizer
  • 12.9. Ono Pharmaceuticals

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us